中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

71 records (took 0.023 seconds)

    MIXTURE OF HMOs
    42.
    发明申请
    MIXTURE OF HMOs 有权

    公开(公告)号：US20230000886A1

    公开(公告)日：2023-01-05

    申请号：US17780869

    申请日：2020-11-27

    Applicant: Glycom A/S

    Inventor： Louise Kristine Vigsnæs ,  Bruce McConnell ,  Dorthe Seitzberg ,  Ingvild Dybdrodt Amundsen

    IPC: A61K31/702 ,  A61P1/12

    Abstract: The invention relates to a human milk oligosaccharide (HMO) for use in, a synthetic composition comprising an HMO for use in, and a method for prophylactically reducing gastrointestinal IBS symptom severity and/or symptom occurrence in a lac-tose-intolerant, IBS patient; reintroducing a source of lactose into the diet of a lactose-intolerant, IBS patient while prophylactically reducing gastrointestinal IBS symptom severity and/or symptom occurrence in the IBS patient; and/or reducing the severity and/or occurrence of non-gastrointestinal symptoms in a lactose-intolerant, IBS patient.

    Synthetic composition for treating metabolic disorders
    44.
    发明授权
    Synthetic composition for treating metabolic disorders 有权

    公开(公告)号：US11529364B2

    公开(公告)日：2022-12-20

    申请号：US17093337

    申请日：2020-11-09

    Applicant: GLYCOM A/S

    Inventor： Emma Elison ,  Bruce McConnell ,  Thierry Hennet ,  Louise Kristine Vigsnæs

    IPC: A61K31/702 ,  A61K31/7012 ,  A61K31/7004 ,  A61K9/00

    Abstract: A method for treating metabolic disorders in non-infant includes administering to an obese non-infant human during a treatment period an effective amount of a mixture of two or more synthetic neutral human milk oligosaccharides (HMOs) selected from 2′-fucosyllactose (2′FL), 3-fucosyllactose (3-FL), difucosyllactose (DFL), lacto-N-fucopentaose I (LNFP-I), lacto-N-tetraose (LNT), and lacto-N-neotetraose (LNnT), and optionally one or more excipients. The method further includes increasing in the gastrointestinal microbiota of the non-infant human during the treatment period, the relative abundance of Bifidobacterium adolescentis and reducing in the non-infant human during the treatment period, a precursor condition for a metabolic disorder associated with development of one or more of obesity-induced pre-diabetes and type 2 diabetes, the precursor condition selected from gut permeability, metabolic endotoxemia, low-grade metabolic inflammation, and body fat percentage.

    SYNTHETIC COMPOSITION FOR PREVENTING OR TREATING CVD
    48.
    发明申请
    SYNTHETIC COMPOSITION FOR PREVENTING OR TREATING CVD 有权

    公开(公告)号：US20210393657A1

    公开(公告)日：2021-12-23

    申请号：US17239889

    申请日：2021-04-26

    Applicant: GLYCOM A/S

    Inventor： Louise Kristine Vigsnæs ,  Bruce McConnell ,  Emma Elison

    IPC: A61K31/702 ,  A61K35/745 ,  A61K9/20 ,  A61K9/48 ,  A23L33/21 ,  A23L33/135

    Abstract: A method for reducing the likelihood of a non-infant human experiencing a cardiovascular disease (CVD) associated with hypercholesterolemia, hypertension, or a metabolic disorder such as type II diabetes and/or insulin resistance. Various examples of the method include selecting an amount of one to five human milk oligosaccharides (HMOs) selected from the fucosylated HMOs 2′-fucosyllatcose (2′-FL), difucosyllactose (DFL), 3-fucosyllactose (3-FL), and lacto-N-fucopentaose I (LNFP-I) and the non-fucosylated neutral HMOs lacto-N-tetraose and lacto-N-neotetraose that is effective for increasing the relative abundance of Bifidobacterium adolescentis in the gastrointestinal microbiota of the non-infant human; increasing the relative abundance of Bifidobacterium adolescentis in the gastrointestinal microbiota of the non-infant human and reducing serum levels of low-density lipoprotein (LDL) cholesterol and/or increasing GLP-1 or reducing hypertension in the non-infant human by administering the selected amount of the selected HMOs during an initial treatment phase.

Patent Agency Ranking